These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

8810 related articles for article (PubMed ID: 23226618)

  • 1. Downregulation of Noxa by RAF/MEK inhibition counteracts cell death response in mutant B-RAF melanoma cells.
    Basile KJ; Aplin AE
    Am J Cancer Res; 2012; 2(6):726-35. PubMed ID: 23226618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma.
    Shao Y; Aplin AE
    Cell Death Differ; 2012 Dec; 19(12):2029-39. PubMed ID: 22858545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic.
    Cragg MS; Jansen ES; Cook M; Harris C; Strasser A; Scott CL
    J Clin Invest; 2008 Nov; 118(11):3651-9. PubMed ID: 18949058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BH3 mimetics potentiate pro-apoptotic activity of encorafenib in BRAF
    Hartman ML; Gajos-Michniewicz A; Talaj JA; Mielczarek-Lewandowska A; Czyz M
    Cancer Lett; 2021 Feb; 499():122-136. PubMed ID: 33259900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells.
    Basile KJ; Abel EV; Aplin AE
    Oncogene; 2012 May; 31(19):2471-9. PubMed ID: 21996740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ERK2 phosphorylation of serine 77 regulates Bmf pro-apoptotic activity.
    Shao Y; Aplin AE
    Cell Death Dis; 2012 Jan; 3(1):e253. PubMed ID: 22258404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutant B-RAF mediates resistance to anoikis via Bad and Bim.
    Boisvert-Adamo K; Aplin AE
    Oncogene; 2008 May; 27(23):3301-12. PubMed ID: 18246127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1.
    Wang YF; Jiang CC; Kiejda KA; Gillespie S; Zhang XD; Hersey P
    Clin Cancer Res; 2007 Aug; 13(16):4934-42. PubMed ID: 17652623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma.
    Yadav V; Zhang X; Liu J; Estrem S; Li S; Gong XQ; Buchanan S; Henry JR; Starling JJ; Peng SB
    J Biol Chem; 2012 Aug; 287(33):28087-98. PubMed ID: 22730329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mcl-1 is required for melanoma cell resistance to anoikis.
    Boisvert-Adamo K; Longmate W; Abel EV; Aplin AE
    Mol Cancer Res; 2009 Apr; 7(4):549-56. PubMed ID: 19372583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms.
    Paraiso KH; Haarberg HE; Wood E; Rebecca VW; Chen YA; Xiang Y; Ribas A; Lo RS; Weber JS; Sondak VK; John JK; Sarnaik AA; Koomen JM; Smalley KS
    Clin Cancer Res; 2012 May; 18(9):2502-14. PubMed ID: 22351686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells.
    Shao Y; Aplin AE
    Cancer Res; 2010 Aug; 70(16):6670-81. PubMed ID: 20647317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitogen-activated protein kinase inhibition induces translocation of Bmf to promote apoptosis in melanoma.
    VanBrocklin MW; Verhaegen M; Soengas MS; Holmen SL
    Cancer Res; 2009 Mar; 69(5):1985-94. PubMed ID: 19244105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR signaling defines Mcl⁻1 survival dependency in neuroblastoma.
    Nalluri S; Peirce SK; Tanos R; Abdella HA; Karmali D; Hogarty MD; Goldsmith KC
    Cancer Biol Ther; 2015; 16(2):276-86. PubMed ID: 25756510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective involvement of BH3-only proteins and differential targets of Noxa in diverse apoptotic pathways.
    Zhang L; Lopez H; George NM; Liu X; Pang X; Luo X
    Cell Death Differ; 2011 May; 18(5):864-73. PubMed ID: 21113147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of loss of BH3-only proteins on the development and treatment of MLL-fusion gene-driven AML in mice.
    Bilardi RA; Anstee NS; Glaser SP; Robati M; Vandenberg CJ; Cory S
    Cell Death Dis; 2016 Sep; 7(9):e2351. PubMed ID: 27584789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma.
    Ramakrishnan VG; Miller KC; Macon EP; Kimlinger TK; Haug J; Kumar S; Gonsalves WI; Rajkumar SV; Kumar SK
    Haematologica; 2019 Oct; 104(10):2061-2074. PubMed ID: 30846494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel BH3 mimetic efficiently induces apoptosis in melanoma cells through direct binding to anti-apoptotic Bcl-2 family proteins, including phosphorylated Mcl-1.
    Liu Y; Xie M; Song T; Sheng H; Yu X; Zhang Z
    Pigment Cell Melanoma Res; 2015 Mar; 28(2):161-70. PubMed ID: 25324174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.
    Atefi M; von Euw E; Attar N; Ng C; Chu C; Guo D; Nazarian R; Chmielowski B; Glaspy JA; Comin-Anduix B; Mischel PS; Lo RS; Ribas A
    PLoS One; 2011; 6(12):e28973. PubMed ID: 22194965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression.
    Phadke MS; Sini P; Smalley KS
    Mol Cancer Ther; 2015 Jun; 14(6):1354-64. PubMed ID: 25873592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 441.